immune thrombocytopenic purpura
Haematology · 2010–2022
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| romiplostim and eltrombopag Extension of PBS restrictions for thrombopoietin receptor agonists (TPO-RA) romiplostim and eltrombopag for the treatment of immune thrombocytopenia (ITP) in… | May 2022 | Recommended with restriction | no section in document |
| eltrombopag Treatment of severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) in adult patients; minor submission requesting amendment to allow switching… | Nov 2014 | Not recommended | unclear |
| eltrombopag Initial treatment of severe thrombocytopenia in adult patients with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are splenectomised or… | Mar 2011 | Recommended with restriction | no section in document |
| romiplostim Initial and continuing treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are either… | Mar 2010 | Recommended with restriction | no section in document |
| romiplostim Initial and continuing treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are either… | Mar 2010 | Recommended with restriction | no section in document |
What the PBS pays
$83M in government benefit over 2024–25, across 35,124 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| romiplostim and eltrombopag | $41.7M |
| eltrombopag | $27M |
| romiplostim | $14.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.